Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for biomarkers to catch pancreatic cancer before it strikes

NCT ID NCT07709052

Diagnosis Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell models. The goal is to improve early detection and risk assessment for pancreatic ductal adenocarcinoma, a cancer that is often diagnosed too late.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a test that identifies which patients with pancreatic cysts or precancerous changes are at high risk of developing pancreatic cancer, enabling earlier intervention.
What could go wrong
This is an observational study, not a treatment trial. The biomarkers identified may not prove accurate enough for clinical use, and results from lab-grown tumor models may not reflect real patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (≥18 years) referred to the IRCCS "Saverio de Bellis" for pancreatic surgical resection due to suspected pancreatic neoplasm. Eligible participants are those with a histopathologic diagnosis of intraductal papillary mucinous neoplasm (IPMN), pancreatic intraepithelial neoplasia (PanIN), or pancreatic ductal adenocarcinoma (PDAC), with availability of residual tumor tissue not required for routine diagnostics and who have provided written informed consent for use of biological samples in translational research.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Patients undergoing pancreatic surgical resection for suspected pancreatic neoplasm. * Histopathologic diagnosis of intraductal papillary mucinous neoplasm (IPMN), pancreatic intraepithelial neoplasia (PanIN), or pancreatic ductal adenocarcinoma (PDAC). * Availability of residual tumor tissue from the surgical procedure not required for diagnostic purposes. * Signed written informed consent for the use of biological samples for research purposes Exclusion Criteria: * Age \< 18 years. * Surgical procedure performed for neoplasms other than IPMN, PanIN, or PDAC. * Absence of written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraductal papillary mucinous neoplasm of pancreas are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intraepithelial neoplasia pancreatic ductal adenocarcinoma Pancreatic Intraductal Neoplasms pancreatic intraductal papillary-mucinous neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraductal papillary mucinous neoplasm of pancreas Pancreatic ductal adenocarcinoma (PDAC) Pancreatic intraepithelial neoplasia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.